Your Vision Our Site
As a global leader in preclinical ocular research for 20 years with a vast array of supporting resources, Charles River offers an integrated approach to guide new ocular therapeutics from bench to market. Small molecules, biologics, gene therapies and cell based therapies, as well as implantable devices intended for ocular treatment are routinely assessed for efficacy, distribution and safety, for submission to regulatory agencies around the world. Ocular effects of systemic compounds targeted to non-ocular conditions can also be characterized in-vivo using state of the art functional and imaging technology, resulting in a more efficient use of study resources, ultimately providing the benefit of reduced timelines, costs and animal usage.